Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma, Non-Hodgkin 3Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Hodgkin Disease 2Hematologic Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 193fludarabine phosphate 123Peripheral Blood Stem Cell Transplantation 107Etoposide 106Mycophenolic Acid 95Filgrastim 92Doxorubicin 85Whole-Body Irradiation 84Tacrolimus 81Brentuximab Vedotin 80Melphalan 78Busulfan 75Radiotherapy 74fludarabine 68Cyclosporine 67Vinblastine 65Rituximab 60Dacarbazine 56Granulocyte Colony-Stimulating Factor 53Gemcitabine 52Antilymphocyte Serum 51Bleomycin 50Nivolumab 47Methotrexate 47Vincristine 46Prednisone 45Cytarabine 44pembrolizumab 36Carmustine 36Bendamustine Hydrochloride 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hodgkin Disease × relatlimab × Lymphoid × Clear all
NCT05255601 2026-02-25

RELATIVITY-069

Bristol-Myers Squibb

Phase 1/2 Completed
5 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT02061761 2023-03-24

A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Bristol-Myers Squibb

Phase 1/2 Completed
106 enrolled 27 charts
LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡